Chiesi paid roughly $1.9 billion to buy KalVista Pharmaceuticals, an Italian pharma adding a commercial-stage biotech to its portfolio.
The deal includes KalVista’s approved drug — the asset Chiesi is really paying for. KalVista enters as a commercial company, which means Chiesi isn’t buying a pipeline gamble. It’s buying a product already generating sales, with commercial infrastructure in place. That’s a different kind of bet than a development-stage deal at this price.
The $1.9 billion figure reflects what commercial-stage biopharma commands right now: high enough to price in existing revenue, steep enough that the underlying asset has to perform. Per-share price and the premium to KalVista’s unaffected share price weren’t disclosed in early reporting.
Chiesi is a mid-size Italian pharma. KalVista’s deal is part of what the industry is calling a vigorous spring shopping spree.
What does Chiesi actually get for $1.9 billion? The math depends on how the approved drug scales post-close. That number doesn’t pencil if sales plateau.
Close timeline hasn’t been reported.
— Diana Kowalski